These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 31249451)

  • 1. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
    Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
    Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients.
    Kim TY; Jeong WK; Sohn JH; Kim J; Kim MY; Kim Y
    Liver Int; 2015 Nov; 35(11):2416-24. PubMed ID: 25875718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
    Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
    Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous motion of liver correlates to the severity of portal hypertension.
    Gelman S; Sakalauskas A; Zykus R; Pranculis A; Jurkonis R; Kuliavienė I; Lukoševičius A; Kupčinskas L; Kupčinskas J
    World J Gastroenterol; 2020 Oct; 26(38):5836-5848. PubMed ID: 33132638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
    Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
    Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
    Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
    World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease: a prospective cohort study.
    Zykus R; Jonaitis L; Petrenkienė V; Pranculis A; Kupčinskas L
    BMC Gastroenterol; 2015 Dec; 15():183. PubMed ID: 26702818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
    Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
    BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
    Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
    PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Evaluation and Prognosis.
    Hernández-Gea V; Berzigotti A
    Dig Dis; 2015; 33(4):515-23. PubMed ID: 26159268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
    J Hepatol; 2024 Aug; 81(2):248-257. PubMed ID: 38479612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
    Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
    J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.
    Lisotti A; Azzaroli F; Buonfiglioli F; Montagnani M; Cecinato P; Turco L; Calvanese C; Simoni P; Guardigli M; Arena R; Cucchetti A; Colecchia A; Festi D; Golfieri R; Mazzella G
    Hepatology; 2014 Feb; 59(2):643-50. PubMed ID: 24038116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.